The mechanism by which angiogenic factors recruit bone marrow (BM)-derived quiescent endothelial and hematopoietic stem cells (HSCs
Recruitment of endothelial and hematopoietic progenitors and stem cells (HSCs) from the bone-marrow (BM) microenvironment and subsequent mobilization to circulation contributes to tissue vascularization and organogenesis. We showed that release of angiogenic factors by tumor cells mobilizes BM-derived endothelial and hematopoietic cells, which promotes tumor growth 1 and suggests that angiogenic factors may also convey signals that regulate hematopoiesis.
During steady-state conditions, HSCs reside in a quiescent state 2 . Stress induction, including chemotherapy/irradiation, results in the release of chemocytokines that increase stem cell motility 3, 4 , thereby facilitating their entry into a microenvironment where they proliferate, differentiate and are mobilized to the circulation. Despite advances in phenotypic identification of pluripotent HSCs (refs. 5-7) , the molecular pathways involved in the angiogenic factor-mediated recruitment of HSCs for reconstitution of hematopoiesis are not known.
Within the vascular endothelial growth factor (VEGF) family, VEGF-A is a potent mediator of the angiogenic switch 8, 9 . VEGF-A interacts with the tyrosine kinase receptors VEGF receptor-1 (VEGFR1, Flt-1) and VEGF receptor-2 (VEGFR2, Flk-1, KDR). Placental growth factor (PlGF), another member of this family, functions as an angiogenic amplifier by signaling through VEGFR1 (ref. 10) . Mice deficient in VEGFR2 display defects in vasculogenesis and hematopoiesis [11] [12] [13] . Although one study has shown that VEGFR2 is expressed on adult human CD34 + NOD/SCID repopulating cells 14 , murine BM-derived VEGFR2 + cells have been shown to be unable to repopulate lethally irradiated recipients 15 . Therefore, the functional role of VEGFR2 expression on HSCs in the regulation of hematopoiesis remains unclear.
As VEGFR1 -/-mice die from vascular disorganization in early embryogenesis, the role of VEGFR1 in the regulation of hematopoiesis has been difficult to evaluate 16, 17 . Mice deficient in the VEGFR1-kinase domain have an angiogenic 18 , but no apparent hematopoietic defect. Nonetheless, post-natal expression of VEGFR1 seems to be associated with the regulation of hematopoietic cell motility. VEGF-A induces migration of VEGFR1 + myelomonocytic cells in vitro [19] [20] [21] . We showed that VEGF-A and/or angiopoietin-1 mobilize BM-repopulating cells 22 . In Drosophila, VEGF modulates primitive hematopoiesis through enhancing hemocyte motility 23 . Based on these data, we hypothesized that expression of VEGF receptors, in particular VEGFR1, regulate hematopoiesis by increasing HSC motility and recruitment.
We used a myelosuppression model where the role of PlGF
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1 + stem cells from bone-marrow microenvironment and VEGF receptors in the regulation of hematopoietic reconstitution can be tested. Mice were treated with the cytotoxic agent 5-fluorouracil (5FU), which depletes cycling hematopoietic cells 24, 25 . We demonstrate that functional VEGFR1, but not VEGFR2, is present on BM-repopulating HSCs. Inhibition of VEGFR1, but not VEGFR2, blocked HSC cell cycling, differentiation and hematopoietic recovery after BM suppression, resulting in the demise of the treated mice. PlGF restored hematopoiesis following myelosuppression by two distinct mechanisms. In the early phases of BM recovery, PlGF directly promoted recruitment of VEGFR1 + HSC and progenitors, whereas in later stages, PlGF indirectly supported hematopoiesis through metalloproteinase-9 (MMP-9)-mediated release of soluble Kit ligand (sKitL). These studies suggest that PlGF, which is endowed with a low toxicity profile provides for a novel strategy to induce hematopoiesis after chemotherapy/radiation, or in hematological disorders such as myelodysplastic syndromes.
CD34
+ VEGFR1 + cells comprise of NOD/SCID-repopulating cells Hematopoietic stem cells (HSCs) express the antigens CD34 and/or AC133. In unseparated cord blood (CB), 4% of mononuclear cells expressed both VEGFR1 and CD14, whereas a smaller cell fraction (<0.2%) stained for VEGFR1, but not for CD15 and CD14. VEGFR1 was expressed on 6.4 ± 0.5% and 4.3 ± 0.3% of human fetal liver and CB-derived CD34 + and AC133 + cells, respectively ( Supplementary Fig. A online) . VEGFR1 + cells were also detected in the CD38 -population, which comprises a phenotypically primitive population of HSCs.
To (Fig. 1a) . Following Lin -Sca-1 + isolation, 73.5 ± 3.1% (n = 6) of these cells expressed VEGFR1, 29.5% expressed c-Kit and 2.5% double-stained for VEGFR1 and VEGFR2. VEGFR1 + cells were also detected in the SP cells of murine BMMCs (data not shown).
In BALB/c mice, 2 days after 5FU treatment, 5.1 ± 0.3% (n = 6) of BMMCs expressed VEGFR1 as compared with 1.4% prior to treatment (Fig. 1b) (Fig.  1d) . Five months after transplantation, 88% of myeloid (CD11b, Gr-1) and lymphoid (B220, Thy-1) cells in the circulation were of VEGFR1 + donor (Ly5.2) origin (Fig. 1e) , indicating that murine VEGFR1 + BM cells have short-and long-term BM-repopulating capacity.
Activation of VEGFR1 is essential for BM reconstitution 5FU-injected mice treated with IgG (controls) or monoclonal antibody to VEGFR2 had complete hematopoietic reconstitution within three weeks (Fig. 2a) . However, 67% of mice treated with neutralizing antibody to VEGFR1 succumbed within 3 weeks after 5FU-induced BM-suppression (Fig. 2b) . The surviv- Mice were also treated with anti-VEGFR1 () and anti-VEGFR2 (ȣ) alone. a, WBCs were quantified. b, Survival rate was monitored on a daily basis. Survival rate was lower in the VEGFR1-treated versus IgG-treated mice (*, P < 0.001). c and d, Hematopoietic recovery following a single dose of 5FU on day 0 (c) or total body irradiation (TBI) plus carboplatin at day 0 (d) (n = 6 for both) followed by a single dose of either Ad-PlGF (b) or Ad-null (ć) on day 0. d, Recombinant G-CSF (injected subcutaneously day 0-14, í) promotes rapid hematopoietic reconstitution. Extent and duration of less than 2000/µl WBCs was significantly shorter in the Ad-PlGFtreated versus Ad-null-treated 5FU-and carboplatin/irradiation-treated mice. c, *, P < 0.001; d, *, P < 0.005. Error bars represent mean ± s.e.m. for 6-10 mice per group. e-g, H&E staining of BM sections of 5FU-treated mice 10 d after co-injection with neutralizing anti-VEGFR1 (f), anti-VEGFR2 (g) or IgG controls (e). Magnification, × 100. h-m, vWF staining of BM sections 10 d after 5FU treatment in antibody-treated mice (anti-VEGFR1 (i and l), anti-VEGFR2 (j and m) or IgG controls (h and k); megakaryocytes are depicted by arrows). Magnifications, ×100 (h-j); ×400 (k-m).
ing mice had profound delay in hematopoietic recovery (Fig. 2a) . Treatment with either anti-VEGFR2 or anti-VEGFR1 for 4 weeks in non-5FU treated mice did not cause hematopoietic toxicity (Fig. 2a) . These data suggest that signaling through VEGFR1, but not VEGFR2, plays a role in hematopoietic reconstitution after myeloablation.
If VEGFR1 inactivation following myelosuppression delays hematopoietic reconstitution, administration of PlGF, the ligand signaling through VEGFR1 but not VEGFR2, should improve hematopoietic recovery. Mice were treated with 5FU ( Fig. 2c ) or a combination of carboplatin and total body irradiation (TBI) (Fig. 2d) . Following myelosuppression, elevated PlGF levels delivered by adenoviral-vector expressing PlGF (AdPlGF), resulted in faster WBC recovery in the early (day 0-6) and later (day 7-16) phases of BM suppression. Extent and duration of WBC recovery of less than 2000/µl was shorter in the AdPlGF-treated group compared with the Ad-null-treated group ( Fig. 2c and d) . Plasma elevation of PlGF improved WBC recovery similar to that seen after G-CSF treatment (Fig. 2d) , except in the early phases after myelosuppression, at time points where G-CSF is proven to be ineffective 27, 28 .
Inhibition of VEGFR1 impairs hematopoietic recovery
The delayed hematopoietic recovery following myelosuppression was associated with a significantly reduced number of BMMCs in mice injected with anti-VEGFR1, as compared with mice treated with antibody to VEGFR2 or IgG (Figs. 2e, f and g and 3a)
. The BM of 5FU-treated mice injected with anti-VEGFR1 showed a decrease in lineage-committed cells, particularly in the megakaryocytic lineage ( Fig. 2h-m) .
ARTICLES FACS analysis of BM cells confirmed the tri-lineage suppression after treatment with blocking anti-VEGFR1. The frequency of BMMCs expressing erythroid (TER119), myeloid (CD11b, Gr1) and lymphoid (B220) markers was significantly decreased on day 6 after VEGFR1 antibody treatment as compared with IgG controls (Fig. 3b) . There was also a delay in the erythroid and lymphoid recovery in mice receiving anti-VEGFR2, but this did not translate into increased mortality in these mice. The decreased BM cellularity in anti-VEGFR1-treated mice was due to fewer Lin -Sca-1 + (Fig. 3c) and Sca-1 + cells ( Fig. 3d and e ) in S and G 2 /M phase of the cell cycle as compared with anti-VEGFR2-and IgG-treated mice. Because 70% of the mice treated with anti-VEGFR1 succumbed to fatal complications afforded by BM failure, timely activation of the PlGF/VEGFR1 pathway is important for HSC and progenitor recruitment, cell differentiation and restoration of multi-lineage hematopoiesis to avoid lifethreatening complications.
PlGF enhances recruitment and migration of VEGFR1
+ HSCs How does PlGF enhance early phases of hematopoietic recovery? PlGF increased mature WBC counts 2-fold above baseline, with a significant increase in circulating monocytes (Fig. 4a) . Mobilization of hematopoietic cells into circulation followed 
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the kinetics of PlGF plasma elevation (Fig. 4a, insert) . Increased numbers of hematopoietic progenitors capable of forming CFU colonies (CFU-Cs) (Fig. 4b) were found within the PlGF-mobilized cells. PlGF augmented the number of circulating pluripotent hematopoietic cells (CFU-Ss) by 20-fold, as compared with controls three days after adenoviral injection (Fig. 4c) . PlGF also mobilized VEGFR1 + BM-repopulating stem cells that engrafted and rescued lethally irradiated recipients (Fig. 4d) . More than 80% of BM-donor cells were detected in mice transplanted with PlGF-mobilized cells. We found that PlGF and VEGF-A stimulate the release of pro-MMP-9 (Fig. 4e, insert) and induce migration of human CD34
+ cells and cells with stem-cell potential (cobblestone-forming cells, CAFC). This migration was blocked by anti-VEGFR1 (Fig. 4e) . These data suggest that PlGF is a chemoattractant that mediates its effect through VEGFR1, because blockade of VEGFR1 completely abolished HSC and progenitor mobilization in vitro and in vivo.
PlGF restores late phases of hematopoietic recovery
In the absence of exogenous growth factor(s), BM reconstitution is complete within 20-30 days following myelosuppression. Immediately post-BM suppression, quiescent Lin -Sca-1 + HSCs undergo rapid cell cycling to replenish the progenitor-cell pool. Blocking VEGFR1 signaling following myeloablation resulted in a decrease in immature Sca-1 + and Lin -Sca-1 + BM cells in S phase of the cell cycle (Fig. 3c, d and e). In vitro exposure of CD34 + cells to PlGF in the presence of sKitL, thrombopoietin and Flt3/Flk2 ligand had no effect on cell proliferation as determined by cell number, CFU-C and long-term culture-initiating cell assay (data not shown).
Therefore, the mechanism for the differential behavior of HSC in vitro and in vivo could be indirectly mediated through the release of a stem cell-active cytokine and/or through the activation of a protease regulating the bioavailability of cytokines. We demonstrate that PlGF induced matrix metalloproteinase-9 (MMP-9) expression in BM cells (Fig. 5a) . If MMP-9 upregulation is the critical step during PlGF-mediated HSC mobilization, PlGF should not mobilize HSCs in MMP-9 -/-mice. Indeed, plasma elevation of PlGF in wild-type, but not in MMP-9 -/-mice, mobilized mature WBCs (Fig. 5b) , CFU-Cs (Fig. 5c ) and CFU-Ss (Fig. 5d) , especially in later phases of PlGF-induced mobilization.
To confirm the role of PlGF-induced MMP-9 activation in BM recovery, we injected Ad-PlGF in 5FU-treated MMP-9 -/-and MMP-9 +/+ mice. In the early phase of hematopoietic recovery, higher WBC counts were found in Ad-PlGF-treated mice, an MMP-9 independent process ( Supplementary Fig. C online) . In the late phase of hematopoietic recovery, Ad-PlGF improved + BM-repopulating stem and progenitor cells. a, BALB/c mice received Ad-PlGF or Ad-null vector by a single i.v. injection on day 0 (n = 6). a, Total WBCs, monocytes (bar graph) and neutrophil cell counts were quantified. ć, WBCs in AdPlGF-treated group; í, WBCs in Ad-null-treated group; b, neutrophils in Ad-PlGF-treated group; (), neutrophils in Ad-null-treated group. Plasma PlGF levels after adenovirus administration were measured by ELISA (insert). b, Number of mobilized progenitors was quantified by using CFU assays. As compared with Ad-null controls, there was a 14-fold increase in the number of circulating progenitors in Ad-PlGF-treated mice. , CFU-GM; í, CFU-GEMM; í, CFU-M; í, BFU-E. (n = 6; *, P < 0.001). c and d, Pluripotency of mobilized cells was assessed by CFU-S assay (c) and BM repopulating assay (d). c, Mobilized PBMCs from Ad-PlGF (í), Ad-null () and control mice (í) were injected into lethally irradiated recipient mice and spleens were harvested on day 12. CFU-S were counted (*, P < 0.001). ; ć, 5 × 10 4 cells) and Ad-null-treated mice were transplanted into lethally irradiated female recipients (n = 12 per group). In mice injected with as low as 1 × 10 5 PlGF-mobilized PBMC cells, there was a significant improvement in survival of recipient mice versus mice transplanted with Ad-null-derived PBMCs (*, P < 0.05). e, Human CD34 + cells were plated in Matrigel-coated transwells. The chemoattractants PlGF or VEGF were added to the lower chamber, while anti-VEGFR1 was added to both chambers. Data are shown as a percentage of migrated cells (). Migrated cells with stem cell potential were quantified by the capacity of cobblestone formation on wk 5, (CAFC wk 5; í) (n = 3; *, P < 0.001 for migration towards chemoattractant PlGF of cells treated with/without anti-VEGFR1). Bottom, Gelatin zymogram of supernatants from human CD34 + cells stimulated with or without PlGF or VEGF in serum-free medium. Supernatants from CD34 + -cell cultures showed gelatinolytic activity for pro-MMP-9 (92 kD). Error bars represent mean ± s.e.m. for 6 mice per experimental condition (a), and 3 independent experiments (b, c, e).
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WBC recovery in MMP-9 +/+ , but not in MMP-9 -/-mice. The improved WBC recovery in Ad-PlGF-treated MMP-9 -/-mice translated into a slight reduction in the mortality following myelosuppression ( Supplementary Fig. C online) .
We recently showed that MMP-9-mediated release of soluble Kit-ligand (sKitL) is essential for hematopoietic reconstitution 4 . Notably, we detected a 10-fold increase in sKitL plasma levels in Ad-PlGF-treated mice as compared with controls (data not shown). PlGF-mediated MMP-9 activation is not critical during the early, but is necessary during the later phases of hematopoietic recovery following myelosuppression. As PlGF was not able to rescue 5FU-treated MMP-9 -/-mice, we hypothesized that the late phases of BM recovery are indirectly regulated by PlGF-mediated release of sKitL. Therefore, if the release of sKitL after PlGF administration is mediated through MMP-9, significantly lower sKitL levels should be found in PlGF-treated MMP-9 -/-as compared with MMP-9 +/+ mice, which was indeed the case (Fig.  5e) . Because PlGF-mediated upregulation of MMP-9 augmented sKitL plasma levels, we predicted that administration of sKitL would rescue 5FU-myeloablated mice treated with anti-VEGFR1. Plasma elevation of sKitL restored survival (Fig. 6a) , and hematopoietic recovery ( Fig. 6b-d ) of myeloablated mice treated with anti-VEGFR1. Remarkably, 5FU-treated mice injected with neutralizing anti-VEGFR1 showed significantly decreased sKitL plasma levels as compared with VEGFR2-treated or control mice (Fig. 6e) . These data suggest that during late phases of BM recovery PlGF-mediated upregulation of MMP-9 facilitates the release of sKitL, thereby promoting cell differentiation and accelerates hematopoietic reconstitution (Fig. 6f ).
Discussion
We demonstrate here that human and murine HSCs with longterm BM-repopulating capacity express VEGFR1, conveying signals regulating cell cycling and motility. Inhibition of VEGFR1, but not VEGFR2, blocked recruitment of HSCs from their resting microenvironment, thereby retarding hematopoietic reconstitution after myelosuppression. PlGF augmented early phases of hematopoietic recovery by promoting recruitment, chemotaxis and mobilization of VEGFR1 + HSCs and progenitors, while during late phases of BM recovery PlGF-mediated upregulation of MMP-9 facilitated the release of sKitL thereby accelerating hematopoietic reconstitution.
Our data suggest that PlGF activates non-angiogenic pathways and thus serves functions other than regulating angiogenesis. Based on our data, the accumulation of angioblasts within the yolk sac in VEGFR1 -/-mice may not only be due to enhanced commitment to angioblasts 17 , but may be due to impaired cell migration. This appears to be the case in Drosophila, where VEGF-A activation is directly linked to hemocyte motility 23 . How does VEGFR1 activation increase HSC motogenic potential? Chemotaxis of VEGFR1 + HSCs and progenitors accounts for the WBC increase in the early phase of PlGF mobilization. PlGF mobilized CFU-Cs and CFU-Ss in MMP-9 +/+ , but to a lesser extent in MMP-9 -/-mice. In later phases, PlGF-induced cell mobilization was impaired in MMP-9 -/-mice, suggesting that PlGF recruits HSCs and progenitors by a different mechanism. PlGF induces the release of sKitL through MMP-9 activation. sKitL increases motility by promoting cell cycle transition through interaction with its receptor c-Kit 29, 30 . Activation of this pathway accounts for the hematopoietic reconstitution during later phases of BM recovery. Indeed, neutralizing anti-VEGFR1 profoundly diminished plasma elevation of sKitL in myelosuppressed mice during BM recovery, while introduction of sKitL into myelosuppressed mice treated with anti-VEGFR1 completely restored hematopoiesis.
The increase in cell cycling and proliferation of VEGFR1 -/-and MMP-9 +/+ mice 37 were injected with Ad-PlGF and/or Ad-null vector by a single i.v. dose on day 0 (n = 6). b, Total WBC counts were quantified (, Ad-PlGF in MMP-9 +/+ ; í, Ad-null in MMP-9 +/+ ; b, Ad-PlGF in MMP-9 -/-; b, Ad-null in MMP-9 -/-mice; *, P < 0.001). c, Mobilized PBMCs were plated in a colony assay (*, P < 0.01). d, Mobilized PBMCs were injected into lethally irradiated mice and spleen colony formation (CFU-S) was determined (*, P < 0.01; black bar: Ad-null in wild-type mice, red bar: Ad-PlGF in MMP-9 -/-mice, open bar: Ad-PlGF in wild-type mice). e, Plasma levels of sKitL in MMP-9 -/-and MMP-9 +/+ mice were determined by ELISA. , Ad-PlGF in wild type; b, Ad-PlGF in MMP-9 -/-mice; í, Ad-null in wild-type mice; b, Ad-null in MMP-9 -/-mice. Error bars represent mean ± s.e.m. for 6 mice per group (b) and for 3 separate experiments per variable (c, d and e) ARTICLES change HSC survival or colony formation in vitro. These data support other reports in which VEGF-A or PlGF had no major effect on the proliferation or survival of HSCs or progenitors [31] [32] [33] . However, these studies do not rule out the possibility that VEGF/VEGFR internal autocrine signaling pathways may synergize with other cytokines to convey survival signals for repopulating cells.
Although VEGFR2 is expressed on human NOD/SCID-repopulating cells 14 , the functional role of VEGFR2 in the regulation of post-natal hematopoiesis remains unclear. Transplantation of murine VEGFR2 + BM cells failed to reconstitute hematopoiesis in lethally irradiated recipients 15 . These data suggest that murine BM-derived VEGFR2 + cells may mark endothelial progenitors 1, 34 rather than repopulating HSCs. Supporting these observations, we showed only a transient delay in the recovery of lymphoid and erythroid precursors in mice treated with neutralizing anti-VEGFR2. This delay in hematopoietic recovery was not sufficient to induce life-threatening complications, since all mice treated with 5FU and anti-VEGFR2 survived. Anti-VEGFR2 may delay the recovery of certain lineages through interference with the production of lineage-specific cytokines, such as GM-CSF and IL-6 (ref. 35 ). In contrast, mice treated with 5FU and neutralizing anti-VEGFR1 showed a striking impaired tri-lineage cell recovery with prolonged pancytopenia, which resulted in the demise of 70% of treated mice kept under germ-free conditions. The lack of a more profound defect in myelosuppressed mice treated with anti-VEGFR2 seems to be in disagreement with the dramatic defect in blood-island formation observed in VEGFR2-null mice. It is difficult to compare the role of VEGFR2 signaling in the regulation of hematopoiesis in the embryo and adult mice, as there are fundamental differences between the established post-natal BM microenvironment and fragile embryonic blood islands. Adult BM stromal cells provide a fortified cellular scaffold that may be resistant to effects of anti-VEGFR2. Since stromal cells express VEGFR1 36 , it is conceivable that anti-VEGFR1 block MMP-9 expression leading to failure of the recruitment of HSCs. This may explain why anti-VEGFR1 compromises hematopoietic recovery, while inhibition of VEGFR2 has only a marginal effect on stress hematopoiesis. Cohorts of 5FU-treated mice (n = 6 per group) were injected i.p. with neutralizing doses of anti-VEGFR1 or IgG (control) in 3-day intervals starting day 0. Mice were co-injected with AdsKitL or Ad-null vector on day 2. a, Left, Survival rates were monitored (n = 12; *, P < 0.001). ć, 5FU+IgG+AdsKitL; b, 5FU+anti-VEGFR1+AdsKitL; í, 5FU+anti-VEGFR1. Right, Plasma levels of sKitL were determined by ELISA. ć, AdsKitL; í, Ad-null. b-d, BMMCs were counted and H&E staining of femurs of anti-VEGFR1 (b), anti-VEGFR1+AdsKitL (c) and AdsKitL-treated (d) mice was performed for morphological analysis, magnification, ×400. *, P < 0.01 comparing the absolute number of BMMCs in the anti-VEGFR1 vs. the control groups. e, Plasma sKitL levels were measured by ELISA in 5FU-treated mice co-injected with neutralizing doses of mAb to VEGFR1 or IgG (n = 5; *, P < 0.01 comparing sKitL plasma levels in mice treated with anti-VEGFR1 to controls). ć, 5FU+IgG; b, 5FU+anti-VEGFR1; , 5FU+anti-VEGFR2. f, PlGF mediates the early phase of BM recovery through rapid mobilization/chemotaxis of preexisting VEGFR1 + BM-repopulating cells. During the late phase of BM recovery PlGF promotes hematopoiesis primarily through MMP-9 mediated release of sKitL, resulting in enhanced cell motility, cycling and differentiation of VEGFR1 + long-term repopulating cells. Error bars represent mean ± s.e.m. for 2-5 separate experiments (a-e).
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We have shown that plasma elevation of VEGF 165 with or without angiopoietin-1 promoted mobilization of HSCs and CFU-Cs (ref. 22) . Here, we show that, under steady-state conditions, chronic inhibition of VEGFR1 or VEGFR2 had no major effect on hematopoiesis. This is in sharp contrast to the failure of hematopoietic reconstitution and demise of the treated mice by inhibiting VEGFR1 during BM suppression. These data suggest that during steady-state hematopoiesis, VEGFR1 inhibition does not result in a profound impairment in hematopoiesis, because the demand for HSC recruitment is low. In contrast, during stress hematopoiesis activation of VEGFR1 is necessary for hematopoietic reconstitution. This phenomenon is similar to other physiological processes requiring rapid tissue vascularization, where stress angiogenesis driven by the mobilization of VEGFR2 + BM-derived cells is necessary to accelerate neo-angiogenesis 1 . These data suggest that in stress hematopoiesis the molecular switch requires activation of VEGFR1, whereas during stress angiogenesis the molecular switch is driven by VEGFR2 activation.
Based on our data, the clinical use of VEGFR1 inhibitors, but to a lesser degree VEGFR2, delivered in combination with myelosuppressive agents, may result in a life-threatening prolongation of BM suppression. In this respect, suppression of hematopoiesis through VEGFR1 inhibition has two ramifications. On one hand, blocking VEGFR1 may inhibit tumor angiogenesis and growth, but on the other hand, it may introduce unwanted BM toxicity. Nonetheless, since VEGFR1 toxicity is dose-dependent, VEGFR1 inhibitors can be delivered with a manageable toxicity profile. Simultaneous administration of sKitL may reduce BM toxicity caused by blocking VEGFR1 and therefore rescue patients from infection or hemorrhage.
Stress promotes mobilization of BM-derived stem cells that ultimately incorporate, although at very low levels, into specific organs. This low efficiency of incorporation may be reflected in the paucity of readily motile stem cells capable of being recruited from the BM to circulation. PlGF, endowed with a low toxicity profile, allows for mobilization of stem cells to the circulation, facilitating recovery of many stem cells that may ultimately be used for organ restoration.
Our findings introduce the novel paradigm that determination of VEGFR1 and MMP-9 expression should be considered as surrogate markers for evaluating the efficacy and success of stem cell mobilization and engraftment in transplantation settings. It is conceivable that dysregulated MMP-9, VEGFR1 or PlGF expression may be responsible for defects in the stem-cell microenvironment leading to BM failure. In this regard, therapeutic strategies to upregulate VEGFR1, PlGF and MMP-9 may provide an effective means to restore motogenic potential of BM-repopulating cells and help to replenish the stem cell pool after BM transplantation.
Methods
Animals. BALB/c, C57BL/6Ly5.1, C57BL/6Ly5.2 and NOD/SCID mice, from the Jackson Laboratory (Bar Harbor, Maine) and MMP-9 -/-and MMP-9 +/+ 129Sv mice (used after >8 back crosses to CD1) 37 , age-and sex-matched (7-8 wk), weight (>20 g) were maintained in Thorensten units. Animal experiments were performed with approval and authorization of the institutional review board and the Animal Care and Use Committee of Cornell University Medical College, Sloan-Kettering Institute and the UCSF Committee on Animal Research.
Antibodies. Murine cells were stained with the following monoclonal antibodies from PharMingen (San Diego, California): anti-B220 (RA3-6B2), Sca- +/-and Sca-1 +/-BMMCs were separated using a MoFlo cell sorter. VEGFR1 + or VEGFR1 -cells were transplanted into lethally irradiated C57BL/6Ly5.1 mice (n = 12 per group).
For the CFU-S assay, mobilized PBMCs (1 × 10 5 per mouse) of PlGFtreated mice were injected i.v. into lethally irradiated syngeneic recipients (9 Gy) as described 4 .
In vivo antibody-blocking experiments. 5FU-treated (300 mg/kg) BALB/c mice were co-injected intraperitoneally with 800 µg anti-mouse VEGFR1 (clone MF-1), anti-mouse VEGFR2 (clone DC101) or IgG as a control at 2-day intervals starting day 0. Anti-mouse VEGFR1 at 1 µg/ml blocked >90% of PlGF-mediated and >50% of VEGF-mediated activity in vitro.
Cytokine administration. Plasma PlGF and sKitL levels were elevated using a single injection of adenovirus (Ad) vector 22, 42 . Mice received Ad-vector expressing human PlGF (Ad-PlGF) or no transgene (Ad-null) at a concentration of 1 ×10 9 plaque-forming units (p.f.u.) and Ad-vector expressing sKitL (AdsKitL) at a concentration of 1.5 × 10 8 p.f.u. Recombinant G-CSF (R&D Systems) was administered s.c. daily from day 0-14 (50 µg/kg).
Myelosuppressive regiments. Mice received a single i.v. injection of 5FU (300 mg/kg) or carboplatin (1.2 mg) plus total body irradiation (5 Gy) on day 0.
Peripheral blood analysis. Blood was collected from mice by retro-orbital bleeding. WBC and granulocytes counts were determined. Wright/Giemsastained blood smears were analyzed for the presence of monocytes. Plasma samples were collected, and human PlGF and murine sKitL (SCF) measured using an ELISA (R&D Systems, Minneapolis, Minnesota). PBMCs were isolated from heparinized blood after centrifugation over a discontinuous gradient using Lympholyte-M (Cedarlane, Ontario, Canada).
Colony-forming assay. PBMCs (1 × 10 5 ) were plated in a methylcellulosebased colony assay including murine sKitL, IL-3 and human erythropoietin 4 . Colonies were scored after 7 d.
Cell-cycle analysis. BMMCs of 5FU-injected BALB/c mice treated with neutralizing anti-VEGFR1, anti-VEGFR2 or IgG in vivo were labeled with Sca-1- FISH analysis. 4 mo after transplantation, male donor BMMCs were detected in female recipients using the murine Y-chromosome-specific probe M34.
Immunohistochemistry. Sections were incubated with MMP-9 antibody (clone 7-11C, Oncogene, Boston, Massachusetts), biotinylated horse antimouse IgG and A&B reagents (Vector) and the M.O.M. kit (Vector, Burlingame, California) was used. Sections were stained with anti-human vWF/HRP (Dako). Sections were developed with 3,3′-diaminobenzidine substrate and counterstained with eosin or hematoxylin.
In vitro transmigration. Human CD34 + cells (purity>95%) were added to 8-µm-pore Matrigel-coated transwell inserts (Costar, Cambridge, Massachusetts). Recombinant PlGF (R&D Systems; 100 ng/ml) or VEGF-A (R&D Systems; 100 ng/ml) was added to the lower chamber with/without neutralizing anti-VEGFR1 (1µg/ml), which was added to both chambers. Transmigrated cells were placed in cultures to measure the number of CFU-C and CAFC (ref. 4 ).
Statistical analysis.
Results are expressed as mean ± s.e.m. Data were analyzed using the unpaired two-tailed Student's t-test and the log-rank test. P < 0.05 was considered significant.
Note: Supplementary information is available on the Nature Medicine website.
